Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 38 - Medicinal preparations containing peptides
Patents for A61K 38 - Medicinal preparations containing peptides (316,240)
12/2005
12/01/2005WO2005112979A2 Methods of preventing and treating alimentary mucositis
12/01/2005WO2005112978A2 Methods and compositions related to delivery of chemical compounds to invertebrate embryos
12/01/2005WO2005112977A2 Compositions for treatment with glucagon-like peptide, and methods of making and using the same
12/01/2005WO2005112976A2 Probiotic compounds from lactobacillus gg and uses therefor
12/01/2005WO2005112975A1 Use of histones for the early diagnosis and/or preventative therapy of virally-infected living cells and a biochip for carrying out said diagnosis
12/01/2005WO2005112974A2 Peptide-modified polyurethane compositions and associated methods
12/01/2005WO2005112973A1 Sensitization to another anticancer therapy and/or amelioration of a side effect of another anticancer therapy by treatment with a gst-activated anticancer compound
12/01/2005WO2005112972A1 Methods of treating disease with random copolymers
12/01/2005WO2005112971A1 Method for inhibiting angiogenesis and/or lymphangiogenesis
12/01/2005WO2005112970A2 Use of gelsolin to treat infections
12/01/2005WO2005112969A2 Herstatin or intron 8-encoded domain thereof for modulating signaling mediated by igf-1 receptor and erbb receptors
12/01/2005WO2005112968A2 Method of using recombinant human antithrombin for neurocognitive disorders
12/01/2005WO2005112956A1 Use of vanadyl compounds for treating tumorous diseases
12/01/2005WO2005112943A1 Topical cromolyn formulations
12/01/2005WO2005112931A2 Methods related to the treatment of neurodegenerative and inflammatory conditions
12/01/2005WO2005112894A1 Nucleic acid microspheres, production and delivery thereof
12/01/2005WO2005112887A2 Composition comprising intercalated functional-active organic compounds
12/01/2005WO2005112864A2 Method for fostering bone formation and preservation
12/01/2005WO2005112657A1 Method of making protein hydrolysates enriched in aminoacids and the use thereof for the production of functional food and medical food
12/01/2005WO2005112541A2 Adenovirus/alphavirus hybrid vector for the effective administration and expression of therapeutic genes in tumour cells
12/01/2005WO2005097165A3 Il-28 and il-29 cysteine mutants for treating viral infection
12/01/2005WO2005092379A3 Materials and methods for treatment of cancer
12/01/2005WO2005090383A3 Process for preparing macrocyclic dipeptides which are suitable for the treatment of hepatitis c viral infections
12/01/2005WO2005089790A3 Y2/y4 selective receptor agonists for therapeutic interventions
12/01/2005WO2005087954A3 Roles of foxc2, pdgfr, vegfr3 in lymphatic vessel development
12/01/2005WO2005087207B1 Compositions and methods for the treatment of depression and other affective disorders
12/01/2005WO2005086970A3 Novel multipeptide regimen for the treatment of autistic spectrum, behavioral, emotional and visceral inflammation/autoimmune disorders
12/01/2005WO2005082930A3 An immunoreactive 38-kda ferric binding protein of ehrlichia canis and uses thereof
12/01/2005WO2005082404A3 Glp-2 derivatives modified by lipophilic substituents
12/01/2005WO2005082339A3 Medicaments and methods for treating headache
12/01/2005WO2005079767A3 Means for modulation of the effects of opioid-like substances
12/01/2005WO2005078090A3 Antisense oligonucleotides for treating unwanted pigmentation of the skin and hair
12/01/2005WO2005077969A3 Inhibitors of serine proteases, particularly hcv ns3-ns4a protease
12/01/2005WO2005074985A3 Methods of modulating cd200 and cd200r
12/01/2005WO2005074970A3 Neuroprotective dietary supplement
12/01/2005WO2005074888A3 Replacement enzyme cochleates
12/01/2005WO2005069975A3 Lysyl oxidase-like 1 (loxl1) and elastogenesis
12/01/2005WO2005065721A3 Use of an anti-inflammatory compound for the reduction of inflammation secondary to the administration of a lipid-nucleic acid complex
12/01/2005WO2005065015A3 Neutralizing antibodies and methods of use thereof
12/01/2005WO2005058938A3 Helical synthetic peptides that stimulate cellular cholesterol efflux
12/01/2005WO2005054509A3 Assay and treatment
12/01/2005WO2005049061A8 Propylene glycol-containing peptide formulations which are optimal for production and for use in injection devices
12/01/2005WO2005048950A3 Tumor and infectious disease therapeutic compositions
12/01/2005WO2005046721A3 Compositions for reducing bacterial carriage and cns invasion and methods of using same
12/01/2005WO2005037202A3 Methods for modulating angiogenesis
12/01/2005WO2005032595A3 Methods and compositions for the inhibition of stat5 in prostate cancer cells
12/01/2005WO2005032491A3 Methods and compositions for mycoplasma pneumoniae exotoxins
12/01/2005WO2005019251A8 Novel fungal proteins and nucleic acids encoding same
12/01/2005WO2005016126A3 Multifactorial assay for cancer detection
12/01/2005WO2005014806A3 Conserved hbv and hcv sequences useful for gene silencing
12/01/2005WO2005009460A3 Pharmaceutical composition comprising activin a, alk-4 or derivatives thereof for the treatment of ophthalmic disorders or cancer
12/01/2005WO2005007859A3 Rna interference mediated inhibition of acetyl-coa carboxylase gene expression using short interfering nucleic acid (sina)
12/01/2005WO2004096118B1 Composition for improving cognition and memory
12/01/2005WO2004094988A3 Tolerance to graft prior to thymic regeneration
12/01/2005WO2004094649A3 Tolerance to graft following thymic reactivation
12/01/2005WO2004092343A3 Epha2, hypoproliferative cell disorders and epithelial and endothelial reconstitution
12/01/2005WO2004087875A3 Nucleic acid-associated proteins
12/01/2005WO2004085505A3 Long acting biologically active conjugates
12/01/2005WO2004082629A3 Novel cyclosporins
12/01/2005WO2004075845A3 Methods for treating or preventing autoimmune disease using histamine h1 receptor-blocking agents
12/01/2005WO2004043394A3 Modulation of huntingtin interacting protein 1 expression
12/01/2005WO2004020979A3 Methods of assaying for cell cycle modulators using components of the ubiquitin ligation cascade
12/01/2005WO2003049703A8 Chimeric infectious dna clones, chimeric porcine circoviruses and uses thereof
12/01/2005US20050268349 Transgenic mice containing brain-specific membrane-anchored protein gene disruptions
12/01/2005US20050267280 Lactone bearing absorbable polymers
12/01/2005US20050267214 Containing a quinolinecarbonylalkyl group, e.g., N1-[3-[(butylamino)sulfonyl](2-methylpropyl)amino]-2R-hydroxy-1S-(phenylmethyl)propyl]-2S-[(2-quinolinylcarbonyl) amino]butanediamide
12/01/2005US20050267201 Oral pharmaceutical compositions containing taxanes and methods of treatment employing the same
12/01/2005US20050267171 Alpha-and beta-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors
12/01/2005US20050267150 Treating Alzheimer's disease with substituted urea or thiourea-alkylamidolactone compound
12/01/2005US20050267125 High drug load tablet
12/01/2005US20050267063 Antisense modulation of p70 S6 kinase expression
12/01/2005US20050267062 Endothelial growth factors; antiischemic agents; neovascularization
12/01/2005US20050267050 Compositions and methods for treating mdma-induced toxicity
12/01/2005US20050267044 Novel compounds and compositions as cathepsin S inhibitors
12/01/2005US20050267043 Novel inhibitors of hepatitis C virus NS3 protease
12/01/2005US20050267041 Tetrapeptide derivative crystals
12/01/2005US20050267040 Hepatitis C virus inhibitors
12/01/2005US20050267039 IL-16 antagonists
12/01/2005US20050267037 Methods and compositions for treating cancer using proteasome inhibitors
12/01/2005US20050267036 Peptide sequence derived from the C-terminus of CaV2.2. and inhibits the interaction of CaV2.2 with Mint1-PDZ1, a glutathione S transferase fusion protein; neurotransmitter-release angonists of CaV2.2, the pore-forming subunit of N-type of voltage-dependent calcium channels; antinocciceptive agents
12/01/2005US20050267035 Peptide and polypeptide inhibitors of complement C1s
12/01/2005US20050267034 Modified exendins and exendin agonists
12/01/2005US20050267033 Multi-dose erythropoietin formulations
12/01/2005US20050267032 Sulfone-containing prodrugs
12/01/2005US20050267031 procytotoxic agents for use in treating cancer; antitumor agents; has at least one lysine residue, modified by a peptide linkage to an amino acid residue, via the epsilon amino group
12/01/2005US20050267030 Use of deltaPKC peptides for modulation of reactive oxygen species
12/01/2005US20050267029 Compounds which modulate amyloidogenesis and methods for their identification and use
12/01/2005US20050267028 ligands isolated from Moraxella catarrhalis outer membrane protein which binds to carcinoembryonic antigen cell adhesion molecules (CEACAM) receptors, and inhibits bacterial adhesion to CEACAM expressing cells in vitro; drugs and vaccines used in the treatment or prophylaxis of infections
12/01/2005US20050267027 Use of erythropoietin for treatment of cancer
12/01/2005US20050267026 Combination dosing regimen for erythropoietin
12/01/2005US20050267024 Polypeptide, cancer therapy, neovascularization defects, retinopathies, arthritis and psoraisis
12/01/2005US20050267022 Identification of novel factors that block programmed cell death or apoptosis by targeting JNK
12/01/2005US20050267021 Cystatin C as an antagonist of TGF-beta and methods related thereto
12/01/2005US20050267020 Polypeptides derived from inducible hsp70 and pharmaceutical compositions containing the same
12/01/2005US20050267019 Echinocandin derivatives, their method of preparation and their application as anti-fungal agents
12/01/2005US20050267018 Macrocyclic compounds as inhibitors of viral replication
12/01/2005US20050267017 Conformationally constrained C-backbone cyclic peptides
12/01/2005US20050267015 Method of treatment and composition for inhibiting the production of toxic free radical and reactive oxygen species using metalloproteins found in bacteria
12/01/2005US20050267014 Pharmaceutical composition comprising factor VII polypeptides and tranexamic acid
12/01/2005US20050267013 Methods for affecting various diseases utilizing LXR compounds
1 ... 1341 1342 1343 1344 1345 1346 1347 1348 1349 1350 1351 1352 1353 1354 1355 1356 1357 1358 1359 1360 1361 ... 3163